Ret Proto-Oncogene (RET) (C-Term) Peptide
RET
Reactivity: Human
Host: Synthetic
BP, WB
-
- Target See all Ret Proto-Oncogene (RET) products
- Ret Proto-Oncogene (RET)
- Protein Region
- C-Term
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- EMKLVHRDLA ARNILVAEGR KMKISDFGLS RDVYEEDSYV KRSQGRIPVK
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-RET Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- Ret Proto-Oncogene (RET)
- Synonyms
- c-ret Peptide, cret Peptide, etID315074.13 Peptide, ret1 Peptide, wu:fd13h01 Peptide, X-ret Peptide, ret-A Peptide, xret Peptide, RET Peptide, MTC1 Peptide, CDHF12 Peptide, CDHR16 Peptide, HSCR1 Peptide, MEN2A Peptide, MEN2B Peptide, PTC Peptide, RET-ELE1 Peptide, RET51 Peptide, RET9 Peptide, c-Ret Peptide, ret proto-oncogene receptor tyrosine kinase Peptide, ret proto-oncogene S homeolog Peptide, ret proto-oncogene Peptide, ret Peptide, ret.S Peptide, RET Peptide, Ret Peptide
- Background
-
This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed.
Alias Symbols: CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET-ELE1, RET51
Protein Size: 1114 - Molecular Weight
- 123 kDa
- Gene ID
- 5979
- NCBI Accession
- NM_000323, NP_000314
- UniProt
- P07949
-
You are here:
